Organization
East Penn Rheumatology
1 abstract
Abstract
BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS OF THE PHASE 3 RA-BEACON STUDY Org: Stanford University School of Medicine, Albany Medical College, Rheumazentrum Favoriten, East Penn Rheumatology, Eli Lilly & Company, Indianapolis, United States,